삼성서울병원

Ko En

Hematology-Oncology Kim, Ki Hyun M.D

Expertise
multiple myeloma, amyloidosis, bone marrow transplantation, CAR T-cell therapy
Treament Schedule 07 月
DATE
MON
01
TUE
02
WEB
03
THU
04
FRI
05
SAT
06
SUN
07
MON
08
TUE
09
WEB
10
THU
11
FRI
12
SAT
13
SUN
14
MON
15
TUE
16
WEB
17
THU
18
FRI
19
SAT
20
SUN
21
MON
22
TUE
23
WEB
24
THU
25
FRI
26
SAT
27
SUN
28
MON
29
TUE
30
WEB
31
AM
PM
Treament Schedule 08 月
DATE
THU
01
FRI
02
SAT
03
SUN
04
MON
05
TUE
06
WEB
07
THU
08
FRI
09
SAT
10
SUN
11
MON
12
TUE
13
WEB
14
THU
15
FRI
16
SAT
17
SUN
18
MON
19
TUE
20
WEB
21
THU
22
FRI
23
SAT
24
SUN
25
MON
26
TUE
27
WEB
28
THU
29
FRI
30
SAT
31
AM
PM

Medical Education

2008 Ph.D. in Medicine Doctor of Philosophy, Graduate School, Chungbuk National University, Cheongju, Chungbuk, Korea
1991 Master of Science Master of Science, Graduate School, Seoul National University College of Medicine, Seoul, Korea

Post-Graduate Training

Fellowship   1999~2000 Samsung Medical Center
Residency   1995~1999 Samsung Medical Center
Internship   1991~1992 Seoul National University Hospital

Professional Appointments

2014~Present professor Department of Medicine Sungkyunkwan University School of Medicine
2008~2014 Associate professor Department of Medicine Sungkyunkwan University School of Medicine
2008~2009 Postdoc fellow Dana-Farber Cancer Institute
2002~2008 Assistant professor Division of Hematology/Oncology Department of Medicine Sungkyunkwan University School of Medicine Samsung Medical Center

Professional Memberships

Member Korean Cancer Association
Member American Society of Hematology
Member The International Myeloma Working Group (IMWG)
Member International Myeloma Society
Member International society of amyloidosis (ISA)

Selected Publications

  • JACC CARDIOVASC IMAGING 2021 Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis Kim1, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES
    View PubMed
  • LANCET 2021 10.1016/S0140-6736(21)00592-4 Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Moreau1, P; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Risse, ML; Asset, G; Mace, S; Martin, T
    View PubMed
  • LEUKEMIA 2021 10.1038/s41375-021-01317-y A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis Dispenzieri1, A; Kastritis, E; Wechalekar, AD; Schonland, SO; Kim, K; Sanchorawala, V; Landau, HJ; Kwok, F; Suzuki, K; Comenzo, RL; Berg, D; Liu, GH; Kumar, A; Faller, DV; Merlini, G
    View PubMed
  • BRIT J HAEMATOL 2021 10.1111/bjh.17541 Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Quach1, H; Nooka, A; Samoylova, O; Venner, CP; Kim, K; Facon, T; Spencer, A; Usmani, SZ; Grosicki, S; Suzuki, K; Delimpasi, S; Weisel, K; Obreja, M; Zahlten-Kumeli, A; Mateos, MV
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
    View PubMed